One promising strategy to specifically modulate the rate of glucose utilization in lymphocytes and tumor cells consists in selectively inhibiting glucose uptake in cancer cells; to this aim, selective GLUT1 inhibitors have been tested in preclinical experiments; however, they were associated with excessive toxicity to be used in the clinic [82]. The gene discussed is SLC2A1; the disease is neoplasm.